Bayer Pharmaceuticals Archives - Executive Platforms: Thought Leader Series

Towards Industrialization of Cell Therapy

November 22, 2023

This discussion will focus on the scientific, technical and cultural transformations required to drive towards true industrialization of cell therapies, including: — Jens VogelSVP & Global Head of BiotechBayer Pharmaceuticals Dr. Jens Vogel is SVP & Global Head of Biotech, Bayer Pharmaceuticals Product Supply, leading biologics operations, development and strategy across five sites, including cell & gene therapy industrialization. Jens has more than 20 years of professional and leadership experience in biologics development, operations, program management and regulatory affairs. Before rejoining Bayer in March 2020, he was President and CEO of Boehringer Ingelheim Fremont and member of BI’s Biopharma Executive…

Towards Industrialization of Cell Therapy

November 23, 2022

Cell therapy, such as regenerative therapies based on iPSCs and adoptive cell therapies targeting cancer with CAR-T cells, CAR-NKs or TCRs hold enormous potential for the future of medicine, enabling for the first time curative approaches. However, the field is still in its infancy and CMC remains a critical bottleneck in bringing these therapies to patients on a global scale. This discussion will focus on the scientific, technical and cultural transformations required to drive towards true industrialization of cell therapies, including: The critical challenges in CMC for cell therapies today How more in-depth understanding of cells, their critical quality attributes…

Bayer Pharmaceuticals

Towards Industrialization of Cell Therapy

Towards Industrialization of Cell Therapy

NASCES

NAFS

NAFMS

EUSCES

BMWS

NAFES

NASRS

NAMES

PMWS

NAISS

NAHRES

Categories

Newsletter